Form 4 Filing for Theresa Heggie at BioCryst Pharmaceuticals Inc.

Theresa Heggie, a director at BioCryst Pharmaceuticals Inc. (BCRX), acquired 15,294 shares of Common Stock on June 11, 2026, as part of an automatic non-employee director grant. This grant is subject to the terms of the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. The shares were acquired at no cost, with a post-transaction ownership of 80,646 shares. Additionally, Heggie was granted 33,540 stock options with an exercise price of $8.50, vesting on the first anniversary of the grant date, with an expiration date of June 11, 2036. These options are also part of an automatic non-employee director grant under the same policy. The total number of options held post-transaction is 33,540. The filing, dated June 15, 2026, indicates direct ownership of these securities.